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ABSTRACT
Clostridium difficile infection (CDI) was once
considered a primarily nosocomial concern.
Emerging evidence from the last 20 years has
highlighted a drastic shift in the known
epidemiology of CDI, with disease outside of
hospitals apparently occurring more frequently
and causing severe disease in populations that
were thought to be at low risk. This narrative
review summarises potential pathways for
infection outside of the hospital environment
and highlights likely routes of transmission.
Further, evidence is presented on potential risk
factors for development of disease.
Understanding the epidemiology of CDI
outside of hospitals is essential to the ability
to prevent and control disease in vulnerable
populations.
Keywords: Animal reservoir/source; Clostridium
difficile infection (CDI); Community-associated
CDI; Epidemiology; Risk factors
INTRODUCTION
Clostridium difficile is a spore-forming,
gram-positive, anaerobic bacillus, which is a
frequent cause of antibiotic-associated
diarrhoea, especially amongst hospitalised
patients [1, 2]. The spectrum of disease caused
by C. difficile infection (CDI) can range from
mild diarrhoea to severe conditions such as
fulminant colitis and toxic megacolon resulting
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in death [1, 3]. In 2010, the Society of
Healthcare Epidemiology of America (SHEA)
identified the epidemiology, pathogenesis,
treatment and prevention of infection with C.
difficile as one of the five most important
clinical challenges facing the discipline of
Healthcare Epidemiology [4].
Historically, CDI was considered largely
nosocomial, with exogenous acquisition from
the healthcare environment considered the
main source of colonisation or infection [5].
The capacity of C. difficile to cause disease in the
community was reportedly recognised as early
as 1982 [6], although this disease was still
considered rare in this population only
20 years ago [7, 8]. This article examines the
literature on community-associated (CA) CDI
and the emergence of C. difficile as a cause of
significant disease outside of healthcare
settings. Suggested routes of transmission,
including human, animal, food and
environmental sources, are explored.
Understanding the interaction between
hospital and community cases is paramount in
determining the underlying drivers behind the
apparent global increase in cases of CA-CDI.
This article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any of
the authors. Ethics approval was not required
for this narrative review.
Healthcare-associated vs.
community-associated infection
Defining what is considered
healthcare-associated (HA)- vs. CA-CDI is
essential in determining the validity of case
classifications. Prior to an agreed definition of
what ‘community-associated’ infection
entailed, non-standardised definitions were
applied by a number of authors [7, 9–13].
These resulted in misclassification due to a
failure to determine hospitalisation history in
cases presenting from the community [14].
Recommended standard case definitions
were published by the European Society of
Clinical Microbiology and Infectious Diseases
(ESCMID) Study Group for C. difficile in 2006
[15] and, in early 2007, the Centers for Disease
Control and Prevention (CDC) ad hoc C. difficile
working group recommended similar case
definitions [16]. These definitions have had
wide acceptance and are commonly used to
categorise cases into HA or CA. The definitions
take into account the clinical and
microbiological evidence to establish what a
‘case’ of CDI is and further elucidate whether a
case should be classified as HA or CA. A
summary of the accepted case definitions of
CA- and HA-CDI is shown in Table 1.
The CDC working group noted that these
definitions were ‘‘interim surveillance
definitions and recommendations based on
existing literature and expert opinion that can
help to improve CDAD surveillance and
prevention efforts’’ [16]. Although these were
published as ‘interim’ definitions, they have not
been updated since their release in 2007. The
recently updated European Centre for Disease
Prevention and Control (ECDC) C. difficile
surveillance protocol has not altered these
original definitions [17].
It is likely that current enhanced surveillance
definitions can be improved. Current enhanced
surveillance definitions attribute a case to a
healthcare facility exposure if it occurred within
4 weeks of discharge and provided the case was
in hospital for a minimum of 48 h (HAI CO)
[15, 16]. There are several limitations with this
definition. The necessary minimum 48 h stay as
an inpatient prior to diagnosis for an infection
to be considered potentially HA may not be
necessary, as prolonged exposure to C. difficile is
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not required for infection, and potential sources
of acquisition should be assessed in light of
what is probable, possible or unlikely. Further
evidence is needed to determine whether this
minimum 48 h stay may be resulting in
misclassification of HAI CO cases as CAI cases.
Some patients frequently visit the hospital
for day procedures (e.g. chemotherapy and
dialysis) and, as a result, have not had a
length of stay more than 48 h prior to
diagnosis. With frequent contact with the
hospital environment (which previous studies
have shown can be contaminated with C.
difficile spores [18]) up to 3–4 times per week,
ruling out the hospital as a source of acquisition
may result in misclassification.
There are other circumstances under which
application of the current enhanced
surveillance definitions may be more likely to
result in misclassification. One group is
‘hospital in the home’ (HITH) patients, who
are provided hospital care via in-home medical
visits, however are considered ‘inpatients’ of the
hospital for this period for the reporting of bed
days, and often in the reporting of other HA
infections (i.e. central line-associated
bloodstream infections). While considered
inpatients for reporting purposes, these cases
reside in their home for the duration of their
treatment, and therefore acquisition of the
infection has occurred outside of the hospital
setting. HITH patients should not be considered
inpatients for the purposes of surveillance, and
infections occurring in these populations
should be classified CAI.
In addition, there is little evidence
concerning the number of HAI HCFO cases
who may have been colonised on admission to
hospital and only developed disease after being
exposed to antimicrobials as part of their
Table 1 Clostridium difficile-enhanced surveillance definitions (Source: McDonald et al. [16])
Classification Definition
1. Healthcare facility onset, healthcare
facility-associated infection (HO-HCFA)
A case with symptom onset more than 48 h after hospital admission
2. Community onset, healthcare
facility-associated infection (CO-HCFA)
A case with symptom onset in the community or 48 h or less after
admission to an HCF, provided that symptom onset was less than
4 weeks after the last discharge from an HCF. Community-onset,
HCF-associated cases should be attributed to the HCF from which the
patient was last discharged, providing the patient was an inpatient of
that HCF for more than 48 h
3. Community-associated Clostridium
difficile-associated disease (CA-CDAD)
A case with symptom onset in the community or 48 h or less after
admission to an HCF, provided that symptom onset was more than
12 weeks after the last discharge from an HCF
4. Indeterminate A case who does not fit any of the above criteria for an exposure setting,
e.g. a patient who has symptom onset in the community but who was
discharged from the same or another HCF 4–12 weeks before
symptom onset
5. Unknown A case for whom the exposure setting cannot be determined because of
lack of available data
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medical management. The rates of colonisation
in ‘healthy individuals’ in the community are
relatively low [19, 20]; recent data from a
Canadian study suggest approximately 5% of
patients admitted to hospital may be
asymptomatically colonised [21]; however it is
not clear how much this may vary across
different regions. The work of Eyre and
colleagues on over 1200 hospital cases of C.
difficile over a 3.6-year period found that only
35% of cases were genetically related to at least
one previous case [22]. These data support the
hypothesis that asymptomatic colonisation on
admission to a HCF has a significant impact on
case numbers, even on those deemed HAI
HCFO.
LABORATORY TESTING
FOR CLOSTRIDIUM DIFFICILE
INFECTION
Different diagnostic techniques used by
laboratories have been highlighted as an area
of concern when estimates of CDI prevalence
are being conducted across multiple sites or
countries [23]. Several diagnostic tests are
available for CDI. There are advantages and
disadvantages of various testing methods, often
with trade-offs among sensitivity, specificity,
turn-around time and costs. The available tests
can loosely be grouped into those that detect
the organism, those that detect the toxin and
those that determine whether the organism is
potentially capable of producing toxin by
detecting toxin genes. A summary of the
various testing methods is shown in Table 2.
The ability of different tests to detect
different targets will clearly limit the ability of
some studies to correctly determine which
patients have active disease, which are
asymptomatically colonised with toxigenic
strains and which are harbouring
non-toxigenic strains. To account for variable
positive predictive values (PPVs) in populations
with low prevalence, both ESCMID and the
CDC recommend a two-step testing process,
with a sensitive screening test as the first test
[24, 25]. Currently, no single test is
suitable under all circumstances, and the
outcome (e.g. diagnosis of infection, public
health surveillance) must be taken into
account when performing diagnostic testing.
THE EMERGENCE
OF COMMUNITY-ASSOCIATED CDI
The emergence of, and risk factors for, CA-CDI
have become major areas for research
internationally [26–28]. Most literature
focusing on CDI epidemiology is based on
hospital data. Given the relatively high
proportions of disease and risk factors within
this population, this is not unexpected.
Epidemiological studies of CA-CDI often
include cases that have been detected at a
healthcare facility. This undoubtedly skews the
data, as hospital-identified (HI)-CDI may be
more severe (i.e., severe enough to warrant
presentation at a hospital for treatment) and
under-represented, as an acute care facility is
likely not the primary source of healthcare for
many people living in the community who
develop gastroenteritis symptoms.
The reported incidence of CA-CDI is likely to
vary based on the study population and local
awareness and testing practices. Hospital-based
studies looking at cases of CA-CDI are
suitable to compare prevalence across different
regions, as this allows determination of the
proportion of CA disease in populations
presenting to acute care facilities. This method
is more reliable than trying to determine the
234 Infect Dis Ther (2016) 5:231–251
relative incidence in a community, with
methodological difficulties in determining
catchment populations and testing often at
the discretion of the referring physician [29],
which may lead to under-reporting.
Europe
Under-diagnosis of CDI, particularly among
community cases, has been noted in Europe
[30, 31]. This may be owing to lack of clinical
awareness or non-sensitive laboratory
diagnostic tests [30]. Early reports showed that
even when CA-CDI was considered relatively
uncommon, cases were being identified in
individuals with no recent hospitalisation
history or links to outbreaks in hospitals [32],
suggesting a potential source of infection in the
community.
Using a 90-day cut point for recent
hospitalisation to define a case of ‘probable
community-acquired CDI’, a study using
administrative data in the England over a
12-year period demonstrated an increase in
both the rate and proportion of CAI [33]. The
overall proportion of probable
community-acquired CDI in this study
increased from 7.1% to 13.5%. Consistent
application of the same definition for
surveillance purposes is sufficient to
demonstrate a real increase over time.
A recent multi-centre study across 97
hospitals in 34 European countries applied
enhanced surveillance criteria to 506 CDI cases
Table 2 Diagnostic methods for the detection of C. difficile (adapted from Rupnik et al. [26])
Diagnostic method Advantages Disadvantages
Culture Sensitive Does not differentiate toxigenic and non-toxigenic
strains
Slow
Antigen detection (glutamate
dehydrogenase [GDH])
High negative
predictive value
Fast
Non-specific (requires supplementary testing)
Cytotoxin assay Sensitive
High specificity for
infection
Slow
Enzyme immunoassay Fast Low positive predictive value, particularly in population
with low prevalence
Membrane assays Fast Low positive predictive value, particularly in population
with low prevalence
Real-time PCR Rapid Uncertain specificity for infection
Toxigenic culture High sensitivity Uncertain specificity for infection
Slow
Toxin B gene detection High sensitivity
Fast
Uncertain specificity for infection
High cost
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and found 70/506 (14%) of cases were classified
CA-CDI [34]. The proportion of CA-CDI varied
markedly across countries, ranging from 0% to
82%. As this was a hospital-based study, it is
difficult to assess whether the patient
population and testing practices had a major
influence on rates from the limited information
available.
North America
While CA-CDI is increasingly recognised in the
USA, under-reporting is still suspected [35].
Some large-scale CA-CDI studies have been
undertaken in the USA. A six-centre study in
North Carolina published in 2010 reported a
prevalence of CA-CDI of 20% [36]. In another
multi-centre US study involving eight
geographic areas and 10,342 cases, the
reported prevalence of CA-CDI was 32% [37].
A further important finding of this study was
that one in four patients with CA-CDI was
hospitalised within 7 days of diagnosis,
representing a significant cost and burden to
the healthcare system. Others have reported
even higher rates of hospitalisation (up to 40%)
in CA-CDI cases [38].
Allard and colleagues surveyed 15 hospitals
in Montreal 2005–2006 and, of 2297 cases of
CDI, 599 (27%) were classified as CA-CDI, at a
rate of 32 cases per 100,000 person-years [39].
Similar rates were observed across one reporting
year in another Canadian province (Manitoba)
by Lambert and colleagues, who also reported a
prevalence of 27% and a rate of 23.4 cases per
100,000 person-years [40].
Other Regions
There are few studies on CA-CDI outside of
North America and Europe, perhaps reflecting
an overall lack of C. difficile studies in general
conducted in these regions. A recent
Singapore-based, single-centre study found an
overall prevalence of 13.6% CA-CDI [41], lower
than rates reported in other regions but
nonetheless reflective of CA disease being of
concern in this region. A comprehensive study
of CDI in all Australian jurisdictions was
published in 2014, although CA case data were
not available for all geographical areas [42].
From the data contributed by three states,
Tasmania, Victoria and Western Australia,
CA-CDI comprised 26% of all HI-CDI cases
between 2010 and 2012 [42].
One Kuwait-based study investigated
diarrhoea in 2584 outpatients [43]. Although
this study was not set up to determine the
proportions of CA-CDI and HA-CDI, 16 cases
were identified over a 2-year period, none of
which had been hospitalised in the previous
6 months [43]. These data suggest a low
prevalence of CA-CDI (0.62%) presenting to
this particular facility. There are few data from
South America or Africa describing CA-CDI. It is
unclear whether CDI represents a smaller
burden of disease in these regions, and there is
a lack of public health awareness around the
disease and a lower priority in terms of public
health surveillance and activity or a
combination of these and other factors.
RISK FACTORS
FOR COMMUNITY-ASSOCIATED
CDI
There are several established risk factors for
CA-CDI. There are some similarities and
differences between risk factors in CA and HA
cases [44]. For HA-CDI, advanced age ([65),
antibiotic treatment and co-morbidities are all
recognised risk factors [45, 46]. CA-CDI, on the
other hand, is frequently documented as
occurring in younger populations who lack
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these traditional risk factors [27, 47–51].
Susceptibility to infection to some extent
appears to vary on a case-by-case basis; while
some CA-CDI cases may have many established
risk factors, others seemingly lack the most
important exposures, reflecting our lack of
understanding of this entity. The degree to
which host factors influence susceptibility and
outcomes in disease is still not clear at this
stage. Building a risk profile for CA-CDI may
assist primary care providers in identifying
these cases in the community setting.
Antibiotics and Gastric Acid Suppressants
Antibiotic exposure is the most important risk
factor for all CDI, including CA-CDI
[13, 36, 52–55]. While a meta-analysis
conducted in the USA, focusing on CA-CDI
and antibiotics, supported recent antibiotic
exposure being an important risk factor for
developing CA-CDI [56], this was not uniform
for all antimicrobials. Certain classes
(clindamycin, fluoroquinolones and
cephalosporins) presented the most significant
risk, and others (e.g. tetracyclines) had no
associated increased risk [56]. The discrepant
risk associated with different classes of
antimicrobials has been found by other
researchers [7, 57]. A case-control study
conducted in the UK also found that exposure
to antibiotics in the previous 4 weeks,
particularly multiple agents, was significantly
more frequent among CA-CDI cases than
controls [58].
Although an important risk factor, US
studies on CA-CDI cases have found 32–36%
of those with a documented medication history
had no previous antibiotic exposure in the
preceding 3 months [59, 60]. Further
international studies have shown larger
proportions (43–65%) of CA-CDI cases
compared to HA-CDI cases had no previous
antibiotic exposure [61–64]. Thus antibiotics
have an important, but perhaps not essential,
role in CA-CDI, and other yet to be determined
factors may play a role. Healthcare providers in
the community should be cognisant of
potential for CDI cases presenting with no
prior history of antimicrobial use or
hospitalisation.
Several studies have examined the use of
gastric acid suppressants and their relationship
with CDI [60, 65–67], with varying estimates of
risk for CA-CDI (including nil significant
findings) [68]. The use of PPIs appears to be
particularly significant for the subset of CA-CDI
that is not associated with prior antimicrobial
exposure [60], indicating that the disruption to
the microbiota, which occurs following
exposure to a PPI [69–71], may be sufficient to
cause disease in the absence of antimicrobial
therapy.
Co-morbidities
CDI is a significant problem in populations with
inflammatory bowel disease (IBD) (including
Crohn’s disease), with a high incidence, severe
disease and evidence of increasing rates over
time [72–74]. As patients with a flare in their
IBD have diarrhoea, this leaves open the
possibility that this is being detected more in
this group because of surveillance bias [48]. This
is especially true among Crohn’s patients, half
of whom do not have colonic involvement in
disease [75]. This is, however, unlikely to
account for all of the recent increases in
disease observed in IBD cases, with IBD
patients appearing to have a different
acquisition pattern from the general
population, including increased susceptibility
to a wider range of sources in the community
[76]. There may also be an additional problem
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in that not all patients with an apparent flare in
their IBD are being tested for CDI, leading to
possible under-reporting of the problem.
Other co-morbid conditions are associated
with increased risk of CA-CDI, including
chronic kidney disease, immunodeficiency
(through infection or drug therapy), malignant
lesions and solid organ transplants [27, 77, 78].
Severe co-morbid conditions such as these
increase the risk of CDI because of prolonged
use of antimicrobials and frequent contact with
healthcare facilities [27]. As current definitions
require an inpatient stay of [48 h prior to
diagnosis in order to classify an infection as
HAI, frequent, short-stay hospital visits (such as
those for dialysis or chemotherapy) may not be
captured in this determination.
Contact with Children <2 Years of Age
Identification of C. difficile from neonates has
been long established; the first isolation of this
organism in 1935 was from the stool of healthy
infants [79]. Although relatively rare in healthy
adults, asymptomatic colonisation with
toxigenic C. difficile occurs commonly among
neonates and children \2 years old [80–82].
Acquisition can either occur during the
neonatal period or later on (between 4 and
6 months of age), which corresponds to the
weaning period [80]. Risk factors for
development of disease in children \2 years
appear to differ from the rest of the population
[83] and, as previously noted, true disease as
opposed to concurrent carriage in diarrhoeal
patients may be difficult to discern. More
research is required to determine the scope of
magnitude of CDI in this population [84].
CA-CDI occurs more frequently in females
than males [85, 86]. A 2006 study conducted in
Connecticut found females had nearly twice the
incidence of CA-CDI as males [59], although no
hypothesis was offered for this discrepancy.
CA-CDI has also been described in increasing
numbers of peripartum women, many of whom
do not have any other predisposing factors
[87, 88]. Contact with infants B2 years old is
significantly associated with CA-CDI
[43, 58, 60], and children have been previously
identified as potential reservoirs in the
community [89]. As the usual primary care
givers for neonates and young infants, the
possibility that neonates are responsible for
causing disease in women in the community
warrants further investigation.
TRANSMISSION OF CDI
IN THE COMMUNITY
As C. difficile has traditionally been treated as a
nosocomial infection, much of the literature
around transmission focuses on the hospital
environment, extending into long-term and
similar care facilities. The recognition of this
organism as a cause of diarrhoeal illness in the
community has driven more recent research
efforts towards understanding the acquisition
and transmission of C. difficile outside of the
hospital setting.
In 2010, Otten and colleagues published a
transmission model of CA-CDI as an initial step
towards developing a risk assessment for this
pathogen in the community [90]. The model
contain eight infection states: susceptible,
gastrointestinal exposure, colonised, diseased,
deceased, clinically resolved colonised, relapse
diseased and cleared, with directional transfers
between the states (Fig. 1). The model
represents a complex relationship between
epidemiological states in which a susceptible
individual lacking protective factors becomes
exposed to the organism, which in some cases
leads to a diseased state. Sources of exposure
and risk factors for developing disease once
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exposed are key areas for public health
intervention in order to prevent disease and
halt transmission.
Potential sources of exposure in the
community are discussed in greater details
below, but can be categorised broadly into
consumption (ingestion of spores from a
contaminated food product), person-to-person
contact (transmission from another infected or
colonised person), animal-to-person contact
(transmission from an infected or colonised
domestic or wild animal) and
environment-to-person contact (ingestion of
spores after exposure to a contaminated
environmental source).
Environment
C. difficile contamination of households, even
excluding those of known cases, appears to be
relatively common, with Alam and colleagues
finding an overall prevalence of 32.3% in
household samples [91]. Toxigenic C. difficile
has been found on boots/shoes [91], which
suggests an introduction from contaminated
soil from outside the home. Presence of spores
on kitchen surfaces and refrigerators [92] may
indicate transfer from food products. If the data
collected to date on household contamination
are representative of a typical household,
people may expect to come into contact with
C. difficile in their home environments on a
regular basis.
The many reports on C. difficile outside of the
hospital environment demonstrate that this
organism is ubiquitous in natural settings,
including soils [93–95] and waterways [93, 96],
and inevitably present in environments where
human faecal matter is treated such as waste
water treatment plants [97, 98]. In addition,
Fig. 1 Transmission model of community-associated C. difficile. Otten et al. [90]. Reproduced with permission
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treated animal effluent used to irrigate
agricultural products, and animal manure used
for fertiliser, are other potential environmental
sources [99, 100], with treatment practices not
sufficient to eliminate the spores from the end
product. Thus, there are large numbers of
potential environmental sources for CA-CDI.
Highly discriminatory typing methods may
help to narrow down potential local
environmental sources, including assessment
of the ability of water treatment processes to
remove spores and prevent further spread in the
environment.
The significance of finding low absolute
counts of C. difficile in environmental samples
is unclear—while the ‘infectious dose’ remains
unknown, detection in any number of sources
may or may not be of public health significance
[100]. It is likely that people are coming into
regular contact with a small number of C.
difficile either inside or outside of their home,
which are rarely capable of causing disease
unless the individual has a highly
compromised gut flora. Discrepant individual
practices around hand hygiene, particularly
through hand washing before eating, may also
impact on the significance of environmental
contamination and the possibility of disease
development.
Animals
One potential source of C. difficile transmission
outside of the hospital environment is via
animals. Although many clostridia cause
disease in both humans and animals, these
have not traditionally been considered zoonotic
agents [101]. Molecular studies have, however,
demonstrated common C. difficile isolates in
production animals, companion animals and
humans [102–107], particularly ribotype (RT)
078. As in humans, diarrhoea and C. difficile
colitis have long been associated with
antimicrobial therapy in animals [108].
Outbreaks of CDI have been reported at
veterinary hospitals, affecting hospitalised
dogs [109].
This opens the possibility of C. difficile
sources for human infection in production
(food) animals, companion animals and
native/wild animals. As in neonatal humans,
many young animals are colonised by C.
difficile, which is displaced as the microflora
matures [110]. Unlike humans, neonatal piglets
develop severe diseases including diarrhoea and
respiratory distress and demonstrated high
levels of morbidity and mortality [110–112].
C. difficile has been documented in both
healthy and diseased animals [113]. Recovery
methods may account for variation in
prevalence across studies [114, 115]. The
diseased status, age and species of animal also
influence the reported prevalence
[113, 116–118]. Production (food) animals are
a widely studied group with C. difficile isolated
from pigs, cattle and poultry [115].
In North America, CDI is now considered the
most significant cause of neonatal diarrhoea in
swine [119]. Production animals have
historically been given broad-spectrum
antimicrobials mixed in with feed as a
prophylactic measure for infectious disease
and as a growth promoters [120, 121]. The use
of antimicrobials alters the microflora in
livestock as it does in humans, leaving them
susceptible to CDI. Once the organism is
introduced to a herd, a large number of
susceptible animals living in close quarters can
rapidly become infected. CDI in production
animals is of concern to industry because of
potential growth delays in infected herds [122],
loss of stock [123] and potential contamination
of meat and dairy products, which may damage
consumer confidence.
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Piglets can become colonised within an hour
of birth, in the absence on antimicrobial
treatment [124], perhaps a reflection of
extensive environmental contamination.
Keessen and colleagues demonstrated
widespread aerial dissemination of C. difficile
on a pig farm, with personnel activity
contributing to an increase in numbers [125].
While the consequences of these findings for
human health are not clear, detection of C.
difficile occurred 20 m from the facility that
raises the potential for wider contamination of
the surrounding environment.
Common strains are reported in both animal
populations and human isolates within the
same geographical region [126–128]. Common
strains being found in both humans and
production animals leaves open the possibility
that transmission is occurring from human to
animal rather than the alternative. A small
study conducted by Keessen and colleagues
among pig farm workers found daily to weekly
contact with pigs vs. monthly to less than
yearly contact was significantly associated with
an intestinal presence of C. difficile (p = 0.003)
[129]. These data support the alternative
hypothesis, with workers more likely to be
colonised via frequent contact with the
animals and their environment.
In addition, the organism has been isolated
from companion animals [130–132] and their
role as a reservoir of infection also requires
further investigation. Wild (native) animals
have been investigated and may play a role
spreading C. difficile in the environment
[133, 134]. The detection of C. difficile in
animal populations and the similarities
between strains found in both humans and
animals [126, 128] are suggestive that
transmission between humans and animals is
occurring, either directly or indirectly. Evidence
that certain RTs such as RT 078, which are
prevalent among animals, are now causing
disease in increasing numbers in humans
[104, 106] implies that transmission is
occurring from animals to humans.
While animal-human or human-animal
transmission is biologically plausible, a
common source in the environment that
allows transmission to both groups is an
equally valid suggestion. The ubiquity of C.
difficile in the environment supports this
hypothesis. In the case of wild animal
populations, it seems more plausible that the
presence in these animals is indicative of C.
difficile present in the environment (e.g. via
contamination from treated waste) rather than
a route of human-animal transmission [133].
In order to establish C. difficile as a zoonotic
organism, research must establish an
epidemiological link between animals and
humans who do not share a common
environment that may be a common source of
infection. The most likely scenario in which this
could occur is via the food chain or via water
systems contaminated with the excrement of
colonised or infected animals. Monitoring the
prevalence of C. difficile in animal populations
is useful in veterinary medicine and may further
inform decisions on the use of antimicrobials in
this population. Moreover, longitudinal
analysis of predominant strains in animals is
required to establish links with changes to
strains causing disease in human populations.
Food
The potential for C. difficile to act as a foodborne
pathogen undoubtedly exists, with several
authors examining this potential link. The
majority of studies have focussed on retail
meats, especially beef, pork and poultry
[135–139]. Presumably the detection of
genetically similar strains in animal herds and
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humans has led to an increased awareness of the
potential for C. difficile as a foodborne
pathogen. The potential for secondary
contamination of vegetables, e.g. onions and
salads, has been explored to a lesser extent,
despite early evidence of these foods as a
potential source [93].
RTs 078 and 027 have dominated meat
prevalence surveys in North America
[135, 140–142]. This aligns with the common
RTs from animal studies and suggests that meat
is being contaminated at some point in
processing rather than from another external
source. Although not all RTs were able to be
matched to reference laboratory samples,
matches between RTs found in food samples
and local human cases have been reported
[137, 143, 144]. A lack of standard typing
information across all studies highlights
current inadequacies in nomenclature in the
international literature and the impact this can
have on identifying significant strains across
regions.
The presence of toxigenic spores on
ready-to-eat foods including meat and
vegetables as well as the demonstrated potential
for spores to survive freezing and cooking
processes [145, 146] suggests that ingestion of
spores from contaminated food products and
subsequent infection of a susceptible host is a
plausible scenario. In addition, ribotyping data
show common strains in human and animal
infection [126, 128] although further
whole-genome sequencing will be required to
definitively prove strain relatedness.
Currently, there is insufficient
epidemiological evidence linking the
consumption of contaminated food to
increases of CA-CDI. Unlike other foodborne
outbreaks, there are a number of factors that
may mediate the development of disease.
Unlike salmonellosis or another equivalent
gastrointestinal pathogen, exposure to the
organism, even in a large group of people,
may not result in many or even one case of
infection.
With foodborne pathogens, the infectious
dose is of interest. This has not been established
for C. difficile, and indeed it is not clear if there
is a minimum infectious dose required for a
susceptible host [100]. If this is the case, then
even very low levels of contamination may be
sufficient of cause disease. Weese and colleagues
noted all samples of retail chicken that
contained C. difficile were only positive on
enrichment culture [142]; other studies that
used detection methods with lower sensitivity
may have under-reported the prevalence.
Further, the possibility of laboratory
contamination has been suggested as a
potential explanation for evidence of C.
difficile in food products [147], which can be
dealt with by future researchers with the
inclusion of additional highly discriminatory
techniques, such as whole-genome sequencing.
More evidence is required to provide an
epidemiological link between the consumption
of contaminated food and the development of
CDI and to establish whether foodborne
transmission occurs in the community at a
frequency to cause public health concern.
However, the public health implications and
actions required are unclear; if any level of
exposure in the community might be enough
to precipitate disease development, then
prevention needs to be directed ‘up the chain’,
with implications for the use of antimicrobials in
production animals and handling of carcasses
and meat processing. Public health messages
may best be targeted at the susceptible
population in the community, who may not
always be easily identified and who may not be
able to fully eliminate their risk through
avoidance of potentially contaminated food.
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Human Contacts
The potential for asymptomatic carriers of C.
difficile to shed the organism into the home
environment and cause disease in other
contacts has been demonstrated [148, 149],
although to date there has been no evidence
to support this route as a common mechanism
for disease transmission in the community [5].
This potential may be amplified in the case of
children under 2 years of age and their primary
carers; close contact with faecal matter as part of
caring for these children potentially exposes
carers to a higher level of spores as asymptotic
carriage in this group is high compared with
other healthy individuals [80, 82]. While the
role of asymptomatic carriers is not well
established, this is a plausible mechanism for
transmission in the community, and contact
with potential asymptomatic carriers,
particularly young children, as a driver of
CA-CDI should be explored further.
LIMITATIONS
There are several limitations when it comes to
the interpretation of apparent increases in
CA-CDI in the international literature. An
increased awareness and subsequent
ascertainment bias has been acknowledged as
a potential factor influencing the increase in
incidence [150]. It is logical that an increase in
profile among physicians would result in
increased testing and subsequent case
ascertainment. In order for individual
jurisdictions to monitor the impact of this
bias on reporting, the proportion of positive
cases should be reviewed alongside the raw
numbers of requested tests. These data allow
better interpretation of apparent increasing
rates.
Another factor that needs to be taken into
consideration is variable testing methodologies
across different countries and changes to more
sensitive testing methodologies over time [150].
The former may impact on the prevalence and,
at least partially, account for variable rates. The
latter may give the false appearance of
increasing rates, when the reality is just more
accurate detection methods. While evaluation
of individual laboratory methods used in all
studies was outside the scope of this review,
differences were noted across various studies,
which may account for some of the
heterogeneity in the results.
Taking these limitations into account, it is
still apparent that CA-CDI is increasing, despite
almost certainly being underdiagnosed in the
community [49, 151]. Disease in the
community can be severe, with one study
showing CA-CDI cases were more likely to
develop severe infection than HA-CDI [152].
Further, there is evidence of increasing the
severity of disease among community cases,
using outcomes such as colectomy [153] as a
measure. While hospital-based estimates vary
between facility and region, overall about
one-third of CDI cases currently being
detected in outpatients appear to be CA-CDI.
CONCLUSION
There is evidence of a growing incidence of
CA-CDI worldwide, with cases in the community
resulting in severe disease. While ‘traditional’
risk factors for CDI are well established, cases in
the community lacking in traditional risk factors
are being documented, suggesting such cases
may have different risk factors for disease.
Importantly, there is a paucity of knowledge
around the epidemiology and risk factors for
CA-CDI on a global scale. The available evidence
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suggests close contacts, the environment,
animals (particularly production animals) and
food as potential sources of this infection in the
community. While there has been demonstrable
plausibility for each of these routes of
transmission for CA-CDI, no study has
definitively identified one or a combination of
these as the primary source of infection in the
community. At this stage, the presence of C.
difficile in these reservoirs does not conclusively
prove a causative link; animals and food remain
potential sources of CDI in the community.
More research is required to quantify the burden
of CA infection, and establish whether any of
these suggested risk factors appear to have a
causative role in CA-CDI.
To date, no studies have documented a
transmission route between animals and
humans. Similar strains have been found in
humans and animals; however, while C. difficile
is clearly a zoonotic organism, further research
needs to be undertaken to establish the path of
transmission. At best the evidence is patchy and
further research is required. However, based on
the available evidence, CDI, particularly in the
community, sits firmly under the ‘One Health’
umbrella, in which human health, animal
health and the environment are inextricably
linked. CDI affects human and animal
populations, although the links between the
two require better definition and the messages
around reducing risk in the community are not
clear. Understanding the burden and drivers of
disease in this setting is paramount.
CA-CDI is an emerging concern of public
health significance. It is unlikely that the
prevention and control of this organism
within healthcare facilities will be achievable
until the full dimensions of the problem,
including what is happening outside of the
hospital system, are known.
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